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COVID-19 has brought about unprecedented 
challenges to healthcare systems forcing 
them to meet the sudden increase in demand 
of large numbers of critically ill patients. 
However, the long- term negative impact will 
be on patients without COVID due to lost 
opportunities to undergo standard diagnostic 
testing and treatment in a timely manner.1
We introduced a COVID- adapted 
colorectal cancer pathway at the outset of the 
pandemic in an attempt to mitigate the risks 
of delayed and missed cancer diagnoses. The 
COVID- adapted pathway design was based on 
appraisal of the current literature and used 
the available non- aerosol generating testing 
tools, namely, quantitative faecal immu-
nochemistry testing (qFIT) and CT scan-
ning with oral preparation (figure 1)2–4 and 
triaged patients based on their symptomatic 
risk (high- risk symptoms, including palpable 
abdominal mass, persistent change in bowel 
habit to looser stool not just simple consti-
pation, repeated rectal bleeding without an 
obvious benign anal cause or blood mixed in 
with the stool, abdominal pain with weight 
loss with or without iron deficiency anaemia). 
The qFIT test is routinely used for screening 
and as a triage tool in low- risk populations, 
however it is not used as a rule out test in 
those with potential colorectal cancer due to 
its sensitivity. The threshold of 10 µg/g was 
not used for investigation as data from several 
health boards suggest that the positivity rate 
is ~23%. We, therefore, used the threshold 
of 80 µg/g as based on the Scottish bowel 
screening guidelines.
PATHWAY DESIGN AND ADOPTION
There were inevitable challenges to the 
design, implementation and operation of a 
new pathway during a time when the National 
Health Service (NHS) was put on to an 
emergency footing. While taking advantage 
of standard methodology and conceptual 
framework,5 some adjustments and improv-
isations were required to implement the 
pathway effectively. Swift agreement on broad 
principles and a clear single goal of mitigating 
risks for patients enabled powerful facili-
tation of the pathway. Due to the pressing 
need to implement this alternative pathway, 
wider consultation was not undertaken at the 
outset other than lead stakeholders. We were 
conscious that it could be difficult for clini-
cians to become familiar with the pathway 
design and be fluent at requesting the appro-
priate tests when they had not been directly 
involved in the design process. To circumvent 
this, an online manual was written, accompa-
nied by a step- by- step procedural diagram.
PATHWAY IMPLEMENTATION
The main challenge of pathway implemen-
tation was the requirement for subsequent 
robust management. It required streamlining 
requests for tests, triaging patients who were 
referred urgently with symptoms suspicious 
of colorectal cancer and tracking patient 
flow. This was only possible with engage-
ment from a wide multidisciplinary team, 
including consultant surgeons, gastroenter-
ologists, radiologists and biochemists as well 
as general practitioners and specialist nursing 
staff and support from the NHS health board. 
A bespoke data management system was 
developed using Excel, which enabled us 
to have full grasp of activities and signpost 
patients in a stepwise manner to the tests 
required at each stage. It also allowed iden-
tification of those who did not return their 
qFIT within a specified time period or did not 
attend appointments. Staff members phoned 
these patients to clarify the rationale of the 
pathway and encourage uptake. Live data 
from the pathway allowed real- time analysis 
of pathway performance, including cancer 
detection rate, which was crucial from a clin-
ical governance perspective.6 Demonstrating 
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the benefit of the pathway regularly at departmental 
meetings helped clinical staff to engage with the process 
and retain responsibility for their patients.
In parallel, the pathway operational steps were 
mapped out. Variation and wastage was identified by the 
quality improvement team using a quality management 
approach (figure 2). This provided a clear picture of 
where resources were required (eg, the level of staffing 
and infrastructure needed), and identified barriers and 
constraints requiring solutions. Regular feedback to 
management attempted to facilitate support and resource 
mobilisation. The pathway operation required flexibility 
as logistical and practical adjustments were required over 
time as some diagnostic services slowly resumed. Such 
fluidity and dynamism was achieved by a tightly knit oper-
ational team, including medical, nursing and administra-
tive staff supported by effective leaders.
PATHWAY RESULTS
At the outset, there were many unknown factors, including 
virulence or expected duration of the pandemic. These 
coupled with a lack of specific contextualised clinical 
data to make the pathway completely evidence based led 
to anxieties surrounding its performance. Patients were 
predominantly referred under the urgent suspicion of 
cancer (USOC) category (357), with 48 urgent and 17 
routine referrals being upgraded to USOC by the triaging 
Figure 1 A summary of the COVID- adapted colorectal pathway. Patients were triaged by colorectal consultants with 
information provided from general practice. They proceeded through the pathway in a stepwise fashion being stratified by qFIT 
results. CRC, colorectal cancer; FBC, full blood count; GP, general practitionaer; IDA, iron deficiency anaemia; OPD, outpatients 
department; qFIT, quantitative faecal immunochemical test; USOC, urgent suspicion of cancer; U&E, urea and electrolytes.
Figure 2 Mapping of the pathway process for quality improvement.
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colorectal consultant. We detected cancers in 3.1% (13 
cancers found in included 422 patients) of urgent refer-
rals compared with the expected 3.2% from historical 
practice and significantly outperformed the situation 
should the pathway not have been in existence (0.18% 
cancer detection rate if the service was limited to emer-
gencies only). It achieved the initial purpose and offered 
safety netting for more than 600 patients referred with 
alarm symptoms to a tertiary colorectal unit during the 
pandemic.
PATHWAY MAINTENANCE LONG TERM
Maintenance of the pathway is likely to be required in 
the longer term given the enormity of the pandemic and 
the slow resumption of normal services. No patients were 
discharged on the basis of qFIT tests alone. All patients 
were safety netted either with CT scanning or they 
remained on the list for an outpatient appointment or 
colonoscopy. All patients received letters at each stage 
detailing their results and explaining any safety netting 
procedures they were to receive. This was done in conjunc-
tion with telephone consultations with specialist nurses. 
As previously shown implementation of new pathways is 
not straightforward and requires widespread agreement 
from many. Resource mobilisation, organisational adap-
tations and regular feedback were actively sought from an 
early stage and were essential to maintain change.7 This 
led to increased safety netting procedures being imple-
mented (all patients proceeded to CT) when a variation 
in double qFIT testing was seen.
In conclusion, a transitional service change was 
required due to a rapid change in care provision for those 
patients referred with suspected colorectal cancer during 
the COVID-19 pandemic. Designing, implementing and 
maintaining a bespoke pathway was possible with strong 
leadership, adaptability of staff, flexible multidisciplinary 
team- working and wider support encouraged by regular 
feedback and review of performance.
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